In COVID-19 clinical update #119, Dr. Griffin reviews tixagevimab for infection prevention, ivermectin for outpatient infection treatment, symptom rebound after PAXLOVID treatment, bamlanivimab minimally impacting immune response to vaccination, in-hospital mortality among infection patients, residual viral antigen in patients following infection, usage of Casirvimab/Imdevimab and Remdesivir in infected patients with depleted B-cells, and rheumatic symptoms following infection. Subscribe (free):Apple Podcasts,Google Podcasts,RSS,email Become apatronofTWiV! Links for this episode Tixagevimab-Cilgavimabfor infection prevention (NEJM) Ivermectinfor outpatient infection treatment (medRxiv) Symptom rebound afterPAXLOVID treatment(IDSA) Bamlanivimab minimally impactsimmune response to vaccination (Sci Transl Med) In-hospitalmorality among infectedpatients (IDSA) Casirvimab/Imdevimab & Remdesivirfor infected B-cell depleted patients (IDSA) PAXLOVID patient eligibilityscreening checklist (F...